Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
0.2110
-0.1289 (-37.92%)
At close: Jun 27, 2025, 4:00 PM
0.2081
-0.0029 (-1.37%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Company Description
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
The company’s product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
The company is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc.
Country | United States |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 21 |
CEO | Dane Andreeff |
Contact Details
Address: 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 United States | |
Phone | 215 944 6100 |
Website | heliusmedical.com |
Stock Details
Ticker Symbol | HSDT |
Exchange | NASDAQ |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001610853 |
CUSIP Number | 42328V884 |
ISIN Number | US42328V8845 |
Employer ID | 36-4787690 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Dane Carl Andreeff | President, Chief Executive Officer and Director |
Jeffrey S. Mathiesen CPA | Chief Financial Officer, Treasurer, Secretary and Director |
Dr. Antonella Favit-Van Pelt M.D., Ph.D. | Chief Medical Officer |
Lawrence Picciano | Senior Vice President of Engineering, Quality and Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 27, 2025 | 8-K | Current Report |
Jun 23, 2025 | 8-K | Current Report |
Jun 20, 2025 | 8-K | Current Report |
Jun 13, 2025 | SCHEDULE 13G | Filing |
Jun 10, 2025 | SCHEDULE 13G | Filing |
Jun 10, 2025 | SCHEDULE 13G | Filing |
Jun 6, 2025 | SCHEDULE 13G | Filing |
Jun 6, 2025 | 424B4 | Prospectus |
Jun 4, 2025 | EFFECT | Notice of Effectiveness |
Jun 4, 2025 | 8-K | Current Report |